BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 27885545)

  • 1. Optimization of scan initiation timing after
    Nakajima R; Abe K; Momose M; Fukushima K; Matsuo Y; Kimura K; Kondo C; Sakai S
    Ann Nucl Med; 2017 Feb; 31(2):190-197. PubMed ID: 27885545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of post-treatment metabolic tumor volume from
    Jung TY; Min JJ; Bom HS; Jung S; Kim IY; Lim SH; Kim DY; Kwon SY
    Neurosurg Rev; 2017 Apr; 40(2):223-229. PubMed ID: 27282449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible?
    Tsuyuguchi N; Sunada I; Iwai Y; Yamanaka K; Tanaka K; Takami T; Otsuka Y; Sakamoto S; Ohata K; Goto T; Hara M
    J Neurosurg; 2003 May; 98(5):1056-64. PubMed ID: 12744366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of F-18 FDG and C-11 methionine PET/CT for the evaluation of recurrent primary brain tumors.
    Tripathi M; Sharma R; Varshney R; Jaimini A; Jain J; Souza MM; Bal J; Pandey S; Kumar N; Mishra AK; Mondal A
    Clin Nucl Med; 2012 Feb; 37(2):158-63. PubMed ID: 22228339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery--in malignant glioma.
    Tsuyuguchi N; Takami T; Sunada I; Iwai Y; Yamanaka K; Tanaka K; Nishikawa M; Ohata K; Torii K; Morino M; Nishio A; Hara M
    Ann Nucl Med; 2004 Jun; 18(4):291-6. PubMed ID: 15359921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differentiation of Brain Tumor Recurrence from Post-Radiotherapy Necrosis with 11C-Methionine PET: Visual Assessment versus Quantitative Assessment.
    Minamimoto R; Saginoya T; Kondo C; Tomura N; Ito K; Matsuo Y; Matsunaga S; Shuto T; Akabane A; Miyata Y; Sakai S; Kubota K
    PLoS One; 2015; 10(7):e0132515. PubMed ID: 26167681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of the visual and semiquantitative analysis of carbon-11-methionine PET/CT in brain tumors' recurrence versus post-therapeutic changes.
    Martínez-Amador N; Jiménez-Bonilla J; Martínez-Rodríguez I; De Arcocha-Torres M; Quirce R; Gómez-de la Fuente FJ; López-Defilló JL; Banzo I
    Nucl Med Commun; 2017 Dec; 38(12):1125-1132. PubMed ID: 28906344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Semiquantitative analysis of C-11 methionine PET may distinguish brain tumor recurrence from radiation necrosis even in small lesions.
    Okamoto S; Shiga T; Hattori N; Kubo N; Takei T; Katoh N; Sawamura Y; Nishijima K; Kuge Y; Tamaki N
    Ann Nucl Med; 2011 Apr; 25(3):213-20. PubMed ID: 21188660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy.
    Terakawa Y; Tsuyuguchi N; Iwai Y; Yamanaka K; Higashiyama S; Takami T; Ohata K
    J Nucl Med; 2008 May; 49(5):694-9. PubMed ID: 18413375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of semi-quantification in metabolic PET studies with 18F-fluorodeoxyglucose and 11C-methionine in the determination of malignancy of gliomas.
    Borbély K; Nyáry I; Tóth M; Ericson K; Gulyás B
    J Neurol Sci; 2006 Jul; 246(1-2):85-94. PubMed ID: 16603193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 11C-Methionine Positron Emission Tomography/Computed Tomography Versus 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Evaluation of Residual or Recurrent World Health Organization Grades II and III Meningioma After Treatment.
    Tomura N; Saginoya T; Goto H
    J Comput Assist Tomogr; 2018; 42(4):517-521. PubMed ID: 29613985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3-[123I]iodo-alpha-methyltyrosine and [methyl-11C]-L-methionine uptake in cerebral gliomas: a comparative study using SPECT and PET.
    Langen KJ; Ziemons K; Kiwit JC; Herzog H; Kuwert T; Bock WJ; Stöcklin G; Feinendegen LE; Müller-Gärtner HW
    J Nucl Med; 1997 Apr; 38(4):517-22. PubMed ID: 9098193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET.
    Chung JK; Kim YK; Kim SK; Lee YJ; Paek S; Yeo JS; Jeong JM; Lee DS; Jung HW; Lee MC
    Eur J Nucl Med Mol Imaging; 2002 Feb; 29(2):176-82. PubMed ID: 11926379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?
    Pöpperl G; Kreth FW; Herms J; Koch W; Mehrkens JH; Gildehaus FJ; Kretzschmar HA; Tonn JC; Tatsch K
    J Nucl Med; 2006 Mar; 47(3):393-403. PubMed ID: 16513607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of (11)C-methionine PET parametric response map for monitoring WT1 immunotherapy response in recurrent malignant glioma.
    Chiba Y; Kinoshita M; Okita Y; Tsuboi A; Isohashi K; Kagawa N; Fujimoto Y; Oji Y; Oka Y; Shimosegawa E; Morita S; Hatazawa J; Sugiyama H; Hashimoto N; Yoshimine T
    J Neurosurg; 2012 Apr; 116(4):835-42. PubMed ID: 22242671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases.
    Grosu AL; Astner ST; Riedel E; Nieder C; Wiedenmann N; Heinemann F; Schwaiger M; Molls M; Wester HJ; Weber WA
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1049-58. PubMed ID: 21570201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical interpretation of residual uptake in 11C-methionine positron emission tomography after treatment of basal ganglia germ cell tumors: report of 3 cases.
    Fukuoka K; Yanagisawa T; Watanabe Y; Suzuki T; Matsutani M; Kuji I; Nishikawa R
    J Neurosurg Pediatr; 2015 Oct; 16(4):367-71. PubMed ID: 26140394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of patients with suspected primary and residual/recurrent gliomas.
    Li DL; Xu YK; Wang QS; Wu HB; Li HS
    Chin Med J (Engl); 2012 Jan; 125(1):91-6. PubMed ID: 22340472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of time-activity curves obtained from dynamic
    Nomura Y; Asano Y; Shinoda J; Yano H; Ikegame Y; Kawasaki T; Nakayama N; Maruyama T; Muragaki Y; Iwama T
    J Neurooncol; 2018 Jul; 138(3):649-658. PubMed ID: 29564749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined use of 18F-fluorodeoxyglucose and 11C-methionine in 45 positron emission tomography-guided stereotactic brain biopsies.
    Pirotte B; Goldman S; Massager N; David P; Wikler D; Lipszyc M; Salmon I; Brotchi J; Levivier M
    J Neurosurg; 2004 Sep; 101(3):476-83. PubMed ID: 15352606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.